EXTX — Exact Therapeutics AS Income Statement
0.000.00%
Last trade - 00:00- NOK179.98m
- NOK142.30m
Annual income statement for Exact Therapeutics AS, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
2018 December 31st | R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | NAS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 7.62 | 16 | 34.7 | 59.1 | 40.8 |
| Operating Profit | -7.62 | -16 | -34.7 | -59.1 | -40.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.59 | -14.8 | -33.1 | -58.6 | -40.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.59 | -14.8 | -33.1 | -58.6 | -40.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.59 | -14.8 | -33.1 | -58.6 | -40.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.59 | -14.8 | -33.1 | -58.6 | -40.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.253 | -0.494 | -2.13 | -1.95 | -1.33 |
| Dividends per Share |